EAM Global Investors’s Heron Therapeutics HRTX Stock Holding History

EAM Global Investors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-24,039	Closed	-$761K	–	142
2018 Q3	$761K	Sell	24,039 -6,206	-21%	-$231K	0.31%	145
2018 Q2	$1.18M	Sell	30,245 -37,556	-55%	-$1.2M	0.57%	99
2018 Q1	$1.87M	Buy	+67,801	New	+$1.54M	0.97%	6

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EAM Global Investors's HRTX Position: Q4 2018 in Review

EAM Global Investors sold out of Heron Therapeutics (HRTX) in Q4 2018, closing a stake of 24,039 shares — an estimated $761K sold.

EAM Global Investors first reported a position in HRTX in Q1 2018 and held it in 3 quarters. The position peaked at $1.87M in Q1 2018. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2018.

EAM Global Investors reported no remaining Heron Therapeutics position as of Q4 2018 after selling out during the quarter.
EAM Global Investors sold 24,039 Heron Therapeutics shares in Q4 2018, an estimated $761K.
EAM Global Investors first reported a position in Heron Therapeutics in Q1 2018 and held it in 3 quarters.
EAM Global Investors's Heron Therapeutics position peaked at $1.87M in Q1 2018.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2018.

Based on EAM Global Investors's 13F filing for Q4 2018, filed 13 Feb 2019.